Manulife (Manufacturers Life Insurance)
RPRX icon

Manulife (Manufacturers Life Insurance)’s Royalty Pharma RPRX Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.1M Buy
678,768
+369,031
+119% +$19.2M 0.03% 470
2026
Q1 		$14.9M Buy
309,737
+219,772
+244% +$9.63M 0.01% 696
2025
Q4 		$3.5M Sell
89,965
-191,766
-68% -$7.31M ﹤0.01% 1322
2025
Q3 		$9.94M Buy
281,731
+134,779
+92% +$4.88M 0.01% 861
2025
Q2 		$5.29M Sell
146,952
-281,823
-66% -$9.34M ﹤0.01% 1136
2025
Q1 		$13.3M Buy
428,775
+276,821
+182% +$8.77M 0.01% 722
2024
Q4 		$3.88M Sell
151,954
-73
-0% -$1.94K ﹤0.01% 1304
2024
Q3 		$4.3M Sell
152,027
-127,825
-46% -$3.54M ﹤0.01% 1268
2024
Q2 		$7.38M Sell
279,852
-2,934,926
-91% -$81.4M 0.01% 971
2024
Q1 		$97.6M Buy
3,214,778
+2,660,773
+480% +$78.4M 0.09% 212
2023
Q4 		$15.6M Buy
554,005
+196,775
+55% +$5.41M 0.01% 694
2023
Q3 		$9.7M Sell
357,230
-2,133,184
-86% -$63.4M 0.01% 827
2023
Q2 		$76.6M Sell
2,490,414
-288,246
-10% -$9.76M 0.04% 249
2023
Q1 		$100M Buy
2,778,660
+782,223
+39% +$29M 0.06% 217
2022
Q4 		$78.9M Sell
1,996,437
-395,420
-17% -$16.5M 0.05% 241
2022
Q3 		$96.1M Buy
2,391,857
+2,176,904
+1,013% +$93M 0.07% 199
2022
Q2 		$9.04M Buy
214,953
+42,715
+25% +$1.75M 0.01% 854
2022
Q1 		$6.72M Buy
172,238
+161,857
+1,559% +$6.36M ﹤0.01% 1038
2021
Q4 		$414K Hold
10,381
– – ﹤0.01% 2392
2021
Q3 		$375K Sell
10,381
-124,400
-92% -$4.83M ﹤0.01% 2498
2021
Q2 		$5.53M Sell
134,781
-58,608
-30% -$2.49M ﹤0.01% 1238
2021
Q1 		$8.44M Sell
193,389
-13,966
-7% -$662K 0.01% 1022
2020
Q4 		$10.4M Buy
207,355
+22,734
+12% +$965K 0.01% 872
2020
Q3 		$7.77M Sell
184,621
-31,524
-15% -$1.35M 0.01% 909
2020
Q2 		$9.49M Buy
+216,145
New +$10.7M 0.01% 797

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s RPRX Position: Q2 2026 in Review

Manulife (Manufacturers Life Insurance) increased its Royalty Pharma (RPRX) stake by 119% in Q2 2026, buying an estimated $19.2M and bringing the position to 678,768 shares worth $38.1M. The position accounts for 0.03% of the portfolio, ranked #470.

Manulife (Manufacturers Life Insurance) first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. The position peaked at $100M in Q1 2023. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Manulife (Manufacturers Life Insurance) held 678,768 shares of Royalty Pharma worth $38.1M as of Q2 2026.
  • Manulife (Manufacturers Life Insurance) bought 369,031 Royalty Pharma shares in Q2 2026, an estimated $19.2M.
  • Royalty Pharma made up 0.03% of Manulife (Manufacturers Life Insurance)'s portfolio in Q2 2026, its #470 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
  • Manulife (Manufacturers Life Insurance)'s Royalty Pharma position peaked at $100M in Q1 2023.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2026, filed 14 Aug 2026.